A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries.

Immunization programs epidemiologic monitoring meningococcal infections meningococcal vaccines narrative literature review vaccination policy

Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 13 10 2022
medline: 26 10 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

Immunization is the best strategy to protect individuals from invasive meningococcal disease (IMD). To support decision-making around immunization, this paper considers what has led four countries and regions of two more to introduce the quadrivalent MenACWY vaccine in toddlers (ages 12-24 months). A narrative literature review was conducted to identify countries that have introduced a MenACWY vaccination program for toddlers. Information from peer-reviewed publications, reports, and policy documents for each identified country was extracted. Australia, Chile, the Netherlands, Switzerland, and regions of Italy and Spain have introduced the MenACWY vaccine in their toddler programs, driven by the rising incidence of MenW and MenY and the vaccine's ability to provide protection against other serogroups. Australia and the Netherlands considered the economic impacts of implementing a MenACWY toddler vaccination program. Vaccination uptake and effects are reported for three countries; however, in two, isolating the vaccine's effect from the collateral effect of COVID-related measures is difficult. Increased convergence of vaccination policies and programs is needed internationally, as IMD recognizes no borders.

Identifiants

pubmed: 36222056
doi: 10.1080/14760584.2022.2128771
doi:

Substances chimiques

MenACWY 0
Meningococcal Vaccines 0
Vaccines, Conjugate 0

Types de publication

Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1637-1646

Auteurs

Charalampos Valmas (C)

Value & Access Manager, Market Access Department, Sanofi, Reading, UK.

Emanuele Arcà (E)

Research Consultant, Strategic Market Access, OPEN Health, Rotterdam, The Netherlands.

Marja Hensen (M)

Senior Director, Strategic Market Access, OPEN Health, Rotterdam, The Netherlands.

Habeeda Rashid (H)

Value & Access Associate, Market Access Department, Sanofi, Reading, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH